# Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

> **NCT00278954** · PHASE3 · COMPLETED · sponsor: **Bio Products Laboratory** · enrollment: 50 (actual)

## Conditions studied

- Primary Immunodeficiency
- Common Variable Hypogammaglobulinemia
- X-linked Hypogammaglobulinemia
- Hypogammaglobulinemia
- Immunodeficiency With Hyper-IgM
- Wiskott-Aldrich Syndrome

## Interventions

- **BIOLOGICAL:** Gammaplex (Intravenous immunoglobulin)

## Key facts

- **NCT ID:** NCT00278954
- **Lead sponsor:** Bio Products Laboratory
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278954, "Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00278954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*